Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 310513

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Vaccine
  • Therapeutic
  • Biotechnology
  • Disease
  • Immune
  • Antibody
  • Respiratory
  • DNA
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 310513

License Grant
The Foundation conducted a clinical study for the Company for two phase II clinical trials to determine if a vaccine containing AE37 plus GM-CSF or another peptide vaccine compound (GP2) plus GM-CSF improved patient outcomes. Pursuant to the Forbearance Agreement, the Company and the Foundation in exchange for the Foundations deferring the Company’s overdue payments, future payments and interest, the Company agreed, among other things to pay the Foundation certain royalties and accelerated payments.
License Property
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.

Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. T cells recognize antigenic epitopes when they are ‘presented’ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells, stimulating a multicellular cascade of actions that eliminates the diseased cell and protects against future disease recurrence.

In 2006 Phase I clinical trial was completed of AE37 in breast cancer, including a phase Ib safety and immunology study of AE37 in combination with GM-CSF in 16 breast cancer patients who had completed all first-line therapies and who were disease-free at the time of enrollment to the study (Holmes et al. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;263426-33).

The Foundation conducted the study, under the sponsorship of an institute affiliated with the United States Military until the IND #12229 was transferred to the Company, after which Foundation continued trial management on behalf of the Company.

The Foundation is a nonprofit organization dedicated to advancing medicine by administering, managing and supporting preeminent scientific programs.

Field of Use
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is for the treatment of breast cancer.

Licensee is an oncology company focused on the modulation of the immune system to treat cancer and is developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key.

IPSCIO Record ID: 217567

License Grant
Licensor granted Chinese Licensee an exclusive license to use Licensor’s patents, know-how, data and other intellectual property relating to Licensor’s AE37 peptide to develop and sell products for the prevention and treatment of prostate cancer in China (including Taiwan, Hong Kong and Macau).
License Property
Peptide name AE37 (li-Key/HER2/neu776-790)

AE37 is an immunotherapeutic vaccine for prostate cancer.  AE37, an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.

Trade name AE37

Field of Use
AE37 peptide is to develop and sell products for the prevention and treatment of prostate cancer.

IPSCIO Record ID: 306612

License Grant
Licensor, a nonprofit organization providing investigators and clinicians scientific, granted exclusive worldwide rights to several U.S. and foreign patents and patent applications.
License Property
The patents and patent applications covering methods of using GP2 as an immunotherapy that elicits a targeted immune response against HER2/neu-expressing cancers.

GP2 is an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The patents are titled Vaccine for the Prevention of Breast Cancer Recurrence, and, Targeted Identification of Immunogenic Peptides.

GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. In a Phase IIb clinical trial completed in 2018, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months.

Following breast cancer surgery, a HER2/neu 3+ patient receives Herceptin in the first year, with the hope that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting while Kadcyla has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting.

Patent 1 –
Title Vaccine for the Prevention of Breast Cancer Recurrence
Provisional Patent Application No. 61/121,220

Patent 2 –
Title Targeted Identification of Immunogenic Peptides
as described in U.S. Patent Application No. 12/045,402 filed on 3/10/2008 and Australian Application No. 2008201427 filed on 3/28/2008, both claiming priority to U.S. Provisional Application No. 60/714,865 filed on 09/08/2005 and International Application No. PCT/US2006/035171 filed on 09/08/2006; and
as described in International Application No. PCT/US2006/035171 filed on 09/08/2006 and all corresponding National Stage Applications including but not limited to Japanese Patent Application No. 2008-530244, European Patent Application No. 06824918.4 filed on 3/31/2008, and Canadian Patent Application No. 2,622,036 filed on 3/10/2008; and
as described in International Application No. PCT/GB2008/050227 filed 03/28/2008 and all its corresponding National Stage Applications

Field of Use
The field of use is to develop and advance GP2 immunotherapy towards commercialization.

The Field means (a) all fields of use with respect to Patent titled Vaccine for the Prevention of Breast Cancer Recurrence; and (b) use of the HER family peptide GP2 in combination with Herceptin® and only in the field of human therapeutics with respect to Patent titled Targeted Identification of Immunogenic Peptides.

This agreement is in support of the GP2 breast cancer vaccine Phase II clinical trial.

Licensee believes that GP2 may be used to address the 50% of recurring cancer patients who do not respond to either Herceptin or Kadcyla in the treatment of breast cancer.

IPSCIO Record ID: 344536

License Grant
Licensor grants the Licensee of Korea, an exclusive, non-transferable license, limited to the Licensed Territory and Field of Use, to the Licensed Intellectual Property to use, sell, offer for sale, or otherwise commercially exploit the Licensed Products supplied by Licensee within the Licensed Territory and Field of Use for the Term of this Agreement.
License Property
Licensor shall supply Licensee with Licensed product known as the commercial product NeuVax (E75 peptide in combination with GM-CSF) as a packaged finished product.  NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab.  

The licensed intellectual property includes the following patents
— Methods And Compositions For Stimulating T-Lymphocytes
— Compositions Containing Immunogenic Molecules and Granulocyte-Macrophage Colony Stimulating Factor, as an Adjuvant
— Controlled modulation of amino acid side chain length of peptide antigens
— Vaccine for the Prevention of Breast Cancer Relapse

Field of Use
The Field of Use shall mean for the treatment of breast cancer.

IPSCIO Record ID: 28795

License Grant
Licensor, a non-profit cancer treatment and research institution, grants an exclusive, worldwide right and license, including the right to sublicense, to the Biological Materials and the Licensor Program Patents and interest in Joint Program Patents to discover, develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Materials and Licensed Products and to practice Licensed Processes.

Licensor grants a nonexclusive research and development license for Licensee to practice the use of Licensor' s cancer vaccines identified in the Licensor Patents and the antigens which they contain, to the extent that Licensor has a Valid Claim on any antigens included in any or all vaccines.

License Property
Licensor has been engaged in research efforts focused on the development of conjugated tumor antigens as cancer vaccines.  Licensor plans to conduct human clinical trials on such cancer vaccines which are expected to generate antisera against tumor antigens.

Biological Material shall mean human blood and lymphocytes obtained from patients enrolled in the Participating Licensor Clinical Trials.

The patents include
Ganglioside-KLH Conjugate Vaccines Plus QS21;
Synthesis of glycoconjugates of the globo-h epitope and uses thereof;
Synthesis Of The Breast Tumor-Associated Antigen Defined By Monoclonal Antibody MBR-1 And Uses Thereof;
Polyvalent Conjugate Vaccine for Cancer; and,
Optimal Polyvalent Vaccine for Cancer.

Field of Use
Licensee has expertise in the discovery, development and production of monoclonal antibodies using the lymphocytes of naturally exposed or vaccinated donors.

IPSCIO Record ID: 372471

License Grant
Licensor grants a perpetual, non-terminable, worldwide, exclusive license, with the right to sublicense, under Licensed IP to Develop and Commercialize Licensed Products in the Field.

Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.

License Property
Licensor has developed and owns or has rights to certain Patents and technology relating to developing innovative gene therapies for genetic disorders;

Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement.  Target Antigens will be limited to the oncology associated antigens designated.

T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.

Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.

The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

IPSCIO Record ID: 307944

License Grant
Under the Collobaration Agreement, Licensor will make the Ii-Key Peptide vaccine technology available to the Chinese Licensees. The Chinese parties will provide facilities and personnel for the development of the COVID-19 vaccine under Licensor technical guidance. The development will include synthesis, analysis and human trials through Phase III, if warranted, in China. The Chinese parties will have exclusive rights to use and commercialize the COVID-19 technology and products in China.
License Property
The licensed property is Ii-Key Peptide vaccine technology.  Ii-Key is a technology that activates the immune response for the treatment of cancer and infectious diseases.
Field of Use
The field of use is to develop a COVID-19 vaccine.  The COVID-19 pandemic has opened significant opportunities to resurrect infectious disease vaccine platform Ii-Key Peptide vaccine technology.  COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Licensee is an affiliate of the China Technology Exchange, and is enabling the development of the COVID-19 vaccine in China.

IPSCIO Record ID: 322039

License Grant
The parties collaborated to globally develop and commercialize Licensor’s ladiratuzumab vedotin (MK-6440). The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors.

Licensor granted Licensee an exclusive license to commercialize Tukysa (tucatinib) for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Licensor will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Licensor will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan.

License Property
Ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors.

Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor to treat a type of breast cancer.

HER2-positive cancers is a protein that can promote the growth of breast cancer cells. Breast cancer cells with high levels of HER2 are called HER2-positive.

Licensor is a biotechnology company that study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases including cancer.

Field of Use
The field of use is for the treatment of cancer such as breast cancer.

HER2-positive breast cancer is a type of breast cancer in which breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2).

Licensee is a premier research-intensive biopharmaceutical company that researches medicines and vaccines to prevent and treat diseases including cancers.

IPSCIO Record ID: 28794

License Grant
Licensor, a non-profit cancer treatment and research institution, granted the Company an exclusive, worldwide License under certain U.S. and foreign patents and patent applications owned or controlled by Licensor, or the Licensor's Patents, to develop, manufacture, use, market, sell, offer to sell, import and export certain products related to the development, manufacture, marketing and sale of therapeutic vaccines for the treatment of various cancers.

Subject to certain limitations, the Company will have the right to subLicense the foregoing rights granted.

Licensor grants an exclusive worldwide right and license under the Patent Rights, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice Licensed Processes in the Field of Use.

Licensor grants an exclusive, as it relates to commercial purposes, and not exclusive as it relates to non-commercial purposes, worldwide right and license under the Clinical Data, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice the Licensed Processes in the Field of Use.

Licensor grants a non-exclusive worldwide right and license under the Know How, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice the Licensed Processes in the Field of Use.

License Property
Licensor is the sole owner of certain Patent Rights and Know How relating to Polyvalent Conjugate Vaccines for Cancer.

The patents include, but are not limited to
Ganglioside-KLH Conjugate Vaccines Plus QS21;
Synthetic Compounds Which Bind To H. Pylori And Uses Thereof;
Alpha-O-Linked Glycycoconjugates with Clustered (2,6)-ST Epitopes, Methods of Preparation and Uses Thereof; and,
Polyvalent Conjugate Vaccine for Cancer.

Field of Use
The Field of Use shall mean monovalent and multi-molecular polyvalent cancer vaccines, except that, for the Globo H antigen, Field of Use shall mean multi-molecular polyvalent cancer vaccines. Multi-molecular polyvalent cancer vaccine means a cancer vaccine containing more that one type of antigen but not in the same molecule.

IPSCIO Record ID: 369311

License Grant
Licensor of the Netherlands grants to Licensee of Germany a license under the Licensor Technology  to use, import, develop, market and sell and have used, imported, developed, marketed and sold product in the Field in the NA Territory and the ROW Territory.

This agreement includes a non-exclusive grant back to Licensor by Licensee.

License Property
Licensor has technology related to, inter alia, the development of BLP25.

The Product means BLP25.

BLP25 means Licensors immunotherapeutic vaccine composed of a 25-amino acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant Lipid A and is encapsulated in a liposomal delivery system, together with any improvements thereto, such as liposomal IL-2 in a kit, synthetic Lipid A, or new delivery formats such as unit dose liquid formulations and unit dose syringes.

MUC1 means cancer associated mucin-1.

L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. It is designed to induce an immune response to both the synthetic antigen and the natural corresponding antigen as expressed on the cancer.

Field of Use
BLP25 Liposome Vaccine (L-BLP25) is currently in development for the treatment of non-small cell lung cancer (NSCLC).  Licensee will take over administrative and financial responsibility for the development and commercialization of L-BLP25, including the planned phase 3 trial in NSCLC

The field shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans.

IPSCIO Record ID: 372419

License Grant
This amendment 4 expands the field.  The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases and vaccines, and Licensee now agree to further modify the scope of the Agreement to include new patent families and expand the field to include all therapeutic applications in the Field.
License Property
The license is on a patented specific nucleotide sequence having a triplex structure, referred to as DNA flap.

Gene therapy shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein or other molecule, in order to restore the functional activity of one or more resident non-functional gene copies, or provide for the introduction and expression of novel protein(s) or molecule(s) not normally expressed in the cell type or expression of protein(s) or molecule(s) that do not exist normally in nature.  The introduced protein(s) or molecule(s) are not intended to generate a prophylactic and/or therapeutic immune response against the protein or molecule encoded by the introduced DNA sequence of interest for use in Vaccination.

Field of Use
The Field shall mean Gene therapy for the treatment and prevention of human disorders, including, without limitation, the use of chimeric antigen receptor T-cells.

Chimeric antigen receptor cells is a special receptor created in the laboratory that is designed to bind to certain proteins on cancer cells. The chimeric antigen receptor is then added to immune cells called T cells.

IPSCIO Record ID: 372584

License Grant
Licensor grants a non-exclusive license, including the right to sublicense solely to Affiliates of Licensee, in the Territory under Licensor Use Patent Claims which are determined to include Infringing Claims for use in connection with Covered ODNs outside the Field to the extent otherwise not prohibited by this Agreement.

Licensor grants a non-exclusive license, including the right to sublicense to Permitted Sublicensees, in the Territory under Licensor Process Patent Claims for use in connection with the manufacture of Covered ODNs.

For the Research license,  Licensor grants a nonexclusive, irrevocable, worldwide, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology disclosed to Licensee during the Term; provided that Licensee shall not have any rights to use the Licensor Technology for the sale or manufacture for sale of products or processes.

For Licensees Commercialization Rights, Licensee shall have the right to elect, upon notice to Licensor, to market the Product for the Licensees Indication to Specialty Dermatologists as provided.

License Property
The Licensed Product means any Product, Combination Product, Vaccine Product, Research Product, Research Combination Product or Research Vaccine Product.

Covered ODNs means any Oligodeoxynucleotide which is claimed generically or specifically in a composition of matter claim in an issued patent owned or controlled by Licensee.

Major indication means First line treatment of breast cancer, second line treatment of breast cancer, first line treatment of NSCLC, first line treatment of colorectal cancer, and with respect to Japan only – first line treatment of non-Hodgkins lymphoma, prostate cancer and gastric cancer.

Intermediate indications mean all treatment non-Hodgkins lymphoma and prostate cancer (except for Japan), all treatment of Ovarian cancer, third-line treatment of breast cancer or later treatment of breast cancer,  second-line or later treatment of NSCLC, second-line or third-line  treatment of colorectal cancer.

Minor indication means all treatment of melanoma,  T cell lymphoma, renal cell carcinoma, pancreatic cancer, hematological malignancies (other than non-Hodgkins lymphoma), bladder cancer, uterine cancer, cervical cancers and any other cancers in the field.

Licensees Indication means the treatment, Control or prevention of cutaneous T cell lymphoma, including, without limitation, mycosis fungoides.

Dermatologic disease means basal cell carcinoma in the skin and squamous cell carcinoma in the skin.

Field of Use
The field of use includes the treatment, control or prevention of cancer in humans.

Licensee owns or controls certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides.

IPSCIO Record ID: 27478

License Grant
The Company acquired a new patented T-cell Modulation Process which uses heteroconjugates to direct the body to choose a specific immune response.
License Property
The heteroconjugate technology is intended to selectively stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections and cancer, when it cannot do so on its own.   Administered like vaccines, heteroconjugates combine T-cell binding ligands with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases – clinical studies.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 369291

License Grant
Licensor, a non-profit cancer treatment and research institution, grants an exclusive, sub-licenseable, worldwide license to the Biological Materials Derived Antibodies
—  to develop, have developed, make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, import, have imported, commercialize and have commercialized Licensed Products for use in the Field of Use, and,
—  to perform Licensed Processes in the Field of Use.

Licensor grants a non-exclusive, worldwide, license, explicitly excluding the right to sublicense, to use the Biological Material to develop Licensed Products and Licensed Processes in the Field of Use.

License Property
Licensor is the owner of Biological Material and has the right to grant licenses to Biological Material.

Biological Material means human blood and lymphocytes obtained from patients enrolled in the Licensor Clinical Trial and transferred to Licensee.

Biological Materials Derived Antibodies will mean the specific Antibodies that Licensee has Derived from Biological Material generated from the Licensor Clinical Trial.

Antibodies means an immunoglobin (Ig)molecule, generally comprising four polypeptide chains, two heavy chains (H) and two light (L) chains or an equivalent homologue thereof (e.g. a camelid nanobody, which comprises only a H chain, single domain antibodies (dAbs) which can be either H or L chains); including full length functional mutants, variants, or derivatives thereof, including but not limited to chimeric antibodies, which retain the essential epitope binding features of an Ig molecule and including dual specific, bispecific, multi-specific, and dual variable domain Igs; Igs (e.g. IgG, IgE, IgM)of any class or subclass (e.g. IgG1) and allotype. Also included within the term Antibody is an Antibody fragment, which is a molecule comprising at least one polypeptide chain that is not full length.

Unimolecular Vaccine Patent Rights shall mean all Licensor patents that cover a cancer vaccine comprising two or more carbohydrate-based or MUC-1 antigens linked to a single molecular backbone.

Field of Use
The Field of Use means all human preventative, therapeutic, prognostic, diagnostic and drug discovery applications for Biological Materials Derived Antibodies.

IPSCIO Record ID: 368653

License Grant
For the options and commercial licenses, the Licensor of Switzerland, an international community of scientists focused on cancer research, grants a Non-exclusive, worldwide license, with rights to grant sub-licenses, under Licensor Patent Rights and Know-How to research, develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products in the Field.
License Property
Licensor owns or has the rights to patents including those relating to Full length Antigens and Part Length Antigens.

Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.

Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.

Field of Use
Agreement covers potential antigens being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma.

These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.

This agreements focus is cancer immunotherapy.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.